- Previous Close
1.3300 - Open
1.3000 - Bid 1.3200 x 200
- Ask 1.3500 x 200
- Day's Range
1.2600 - 1.3500 - 52 Week Range
0.1700 - 9.7700 - Volume
550,573 - Avg. Volume
2,369,279 - Market Cap (intraday)
33.778M - Beta (5Y Monthly) -2.88
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6000 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.60
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
www.tempesttx.comRecent News: TPST
View More
Performance Overview: TPST
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TPST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TPST
View MoreValuation Measures
Market Cap
33.78M
Enterprise Value
22.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.99
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.28%
Return on Equity (ttm)
-289.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.75M
Diluted EPS (ttm)
-1.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
31.12M
Total Debt/Equity (mrq)
119.58%
Levered Free Cash Flow (ttm)
-15.2M
Research Analysis: TPST
View MoreCompany Insights: TPST
TPST does not have Company Insights
Research Reports: TPST
View MoreDaily – Vickers Top Buyers & Sellers for 07/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/03/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.